# OnCo record inge-marie-svane (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/inge-marie-svane/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "inge-marie-svane" ;
  schema:name "Inge Marie Svane"@en ;
  schema:description "Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour."@en ;
  schema:url <https://onco.cc/people/inge-marie-svane/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma> ;
  onco:tag "cell-therapy", "til", "melanoma" ;
  schema:jobTitle "Director, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev" ;
  schema:sameAs <https://orcid.org/0000-0002-9451-6037> ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/> ;
  onco:drugs <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:institutions <https://onco.cc/institutions/herlev-hospital/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/> ;
  schema:affiliation <https://onco.cc/institutions/herlev-hospital/> .